The Mechanism of Action of the Anti-Cd38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1597
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Mechanism of Action of a New Anti-Cd38 Antibody: Enhancing Myeloma Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2019English

213Bi Radioimmunotherapy With an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

The Therapeutic Human CD38 Antibody Daratumumab Improves the Anti-Myeloma Effect of Newly Emerging Multi-Drug Therapies

Blood Cancer Journal
OncologyHematology
2011English

Phase I Trial of Isatuximab Monotherapy in the Treatment of Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

CD26 Is a Potential Therapeutic Target by Humanized Monoclonal Antibody for the Treatment of Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Current Use of Monoclonal Antibodies in the Treatment of Multiple Myeloma

British Journal of Haematology
Hematology
2018English

CD38-driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma

Cancer Research
Cancer ResearchOncology
2019English

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

Clinical Cancer Research
Cancer ResearchOncology
2015English

Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy